ALS deficiency caused by an exon 2 deletion and a novel missense variant in the gene encoding ALS

Domené, 2011, Acid-labile subunit (ALS) deficiency, Best Pract. Res. Clin. Endocrinol. Metab., 25, 101, 10.1016/j.beem.2010.08.010 Domené, 2009, Human acid-labile subunit deficiency: Clinical, endocrine and metabolic consequences, Horm. Res., 72, 129, 10.1159/000232486 Domené, 2004, Deficiency of the circulating insulin-like growth factor system associated with inactivation of the acid-labile subunit gene, N. Engl. J. Med., 350, 570, 10.1056/NEJMoa013100 Domené, 2018, Genetic disorders of GH action pathway, Growth Hormon. IGF Res., 38, 19, 10.1016/j.ghir.2017.12.004 Işik, 2017, Clinical and biochemical characteristics and bone mineral density of homozygous, compound heterozygous and heterozygous carriers of three novel IGFALS mutations, Eur. J. Endocrinol., 176, 657, 10.1530/EJE-16-0999 Ertl, 2014, Serumbestimmung von IGF-I, IGF-BP3 und ALS – Neue Referenzwerte laut aktuellen internen Standards, Wien. Med. Wochenschr., 164, 343, 10.1007/s10354-014-0299-4 ALS ELISA E35, 2016, 27 Insert Immulite®2000 IGF-I (ref. PIL2KIGF-1, 2016-04-11), Siemens Healthcare Equipos Médicos SPA Insert Immulite®2000 IGFBP-3 (ref. PIL2KGB-14, 2012-06-18), Siemens Healthcare Equipos Médicos SPA Fofanova-Gambetti, 2010, Impact of heterozygosity for acid-labile subunit (IGFALS) gene mutations on stature: results from the international acid-labile subunit consortium, J. Clin. Endocrinol. Metab., 95, 4184, 10.1210/jc.2010-0489 Richards, 2015, Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology, Genet. Med., 10.1038/gim.2015.30